- Home
- DOUG vs OABI Comparison
DOUG vs OABI Comparison
Compare DOUG & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- OABI
- Stock Information
- Founded
- DOUG 1911
- OABI 2012
- Country
- DOUG United States
- OABI United States
- Employees
- DOUG N/A
- OABI N/A
- Industry
- DOUG Building operators
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- OABI Health Care
- Exchange
- DOUG Nasdaq
- OABI Nasdaq
- Market Cap
- DOUG 225.3M
- OABI 239.0M
- IPO Year
- DOUG N/A
- OABI N/A
- Fundamental
- Price
- DOUG $2.73
- OABI $1.55
- Analyst Decision
- DOUG
- OABI Strong Buy
- Analyst Count
- DOUG 0
- OABI 3
- Target Price
- DOUG N/A
- OABI $6.67
- AVG Volume (30 Days)
- DOUG 382.3K
- OABI 409.7K
- Earning Date
- DOUG 11-03-2025
- OABI 11-04-2025
- Dividend Yield
- DOUG N/A
- OABI N/A
- EPS Growth
- DOUG N/A
- OABI N/A
- EPS
- DOUG N/A
- OABI N/A
- Revenue
- DOUG $1,034,406,000.00
- OABI $23,027,000.00
- Revenue This Year
- DOUG $17.61
- OABI N/A
- Revenue Next Year
- DOUG N/A
- OABI $48.89
- P/E Ratio
- DOUG N/A
- OABI N/A
- Revenue Growth
- DOUG 8.69
- OABI 6.05
- 52 Week Low
- DOUG $1.48
- OABI $1.22
- 52 Week High
- DOUG $3.20
- OABI $4.87
- Technical
- Relative Strength Index (RSI)
- DOUG 52.07
- OABI 41.75
- Support Level
- DOUG $2.46
- OABI $1.64
- Resistance Level
- DOUG $2.89
- OABI $1.75
- Average True Range (ATR)
- DOUG 0.13
- OABI 0.10
- MACD
- DOUG 0.01
- OABI -0.01
- Stochastic Oscillator
- DOUG 69.81
- OABI 2.82
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.